Meta-analysis of real-world survival outcomes of liposomal irinotecan in advanced pancreatic cancer patients with prior irinotecan exposure

被引：0
|
作者：
Gupta, A. [1 ]
Laheru, D. [1 ]
机构：
[1] Johns Hopkins Med, Sidney Kimmel Comprehens Canc Ctr, Med Oncol, Baltimore, MD USA
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.2627
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1680P
引用
收藏
页码：S921 / S921
页数：1
相关论文
共 50 条
  • [41] Survival Benefits of Chemotherapy for Patients with Advanced Pancreatic Cancer in A Clinical Real-World Cohort
    Kordes, Maximilian
    Yu, Jingru
    Malgerud, Oscar
    Liljefors, Maria Gustafsson
    Lohr, J-Matthias
    CANCERS, 2019, 11 (09)
  • [42] A real-world analysis on the efficacy and tolerability of liposomal irinotecan plus 5-fluorouracil and folinic acid in metastatic pancreatic ductal adenocarcinoma in Belgium
    Verbruggen, Lise
    Verheggen, Lisa
    Vanhoutte, Greetje
    Loly, Catherine
    Lybaert, Willem
    Borbath, Ivan
    Vergauwe, Philippe
    Hendrickx, Koen
    Debeuckelaere, Celine
    de Haar-Holleman, Amy
    Van Laethem, Jean-Luc
    Peeters, Marc
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
  • [43] A real-world analysis on the efficacy and tolerability of liposomal irinotecan plus 5-fluorouracil and folinic acid in metastatic pancreatic ductal adenocarcinoma in Belgium
    Verbruggen, Lise
    Verheggen, Lisa
    Vanhoutte, Greetje
    Loly, Catherine
    Lybaert, Willem
    Borbath, Ivan
    Vergauwe, Philippe
    Hendrickx, Koen
    Debeuckelaere, Celine
    de Haar-Holleman, Amy
    Van Laethem, Jean-Luc
    Peeters, Marc
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
  • [44] Clinical Outcomes Among Patients With Metastatic Pancreatic Ductal Adenocarcinoma Treated With Liposomal Irinotecan
    Yu, Kenneth H.
    Hendifar, Andrew E.
    Alese, Olatunji B.
    Draper, Amber
    Abdelrahim, Maen
    Burns, Ethan
    Khan, Gazala
    Cockrum, Paul
    Bhak, Rachel H.
    Nguyen, Catherine
    DerSarkissian, Maral
    Duh, Mei Sheng
    Bahary, Nathan
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [45] Chemotherapy with or without irinotecan in patients with advanced or recurrent gastric cancer: a meta-analysis of randomized controlled trials
    Zeng Chao
    Zhou Hang
    Wei Yang
    Wang Liyang
    Xie Hua
    Yao Wenxiu
    中华医学杂志（英文版）, 2014, 127 (05) : 946 - 951
  • [46] Irinotecan Monotherapy Versus Irinotecan-Based Combination as Second-Line Chemotherapy in Advanced Gastric Cancer: A Meta-Analysis
    Cho, Yo-Han
    Yoon, So Young
    Kim, Soo-Nyung
    CANCER RESEARCH AND TREATMENT, 2017, 49 (01): : 255 - 262
  • [47] Chemotherapy with or without irinotecan in patients with advanced or recurrent gastric cancer: a meta-analysis of randomized controlled trials
    Zeng Chao
    Zhou Hang
    Wei Yang
    Wang Liyang
    Xie Hua
    Yao Wenxiu
    CHINESE MEDICAL JOURNAL, 2014, 127 (05) : 951 - 956
  • [48] Meta-analysis of biweekly irinotecan plus cisplatin versus irinotecan alone as second-line treatment for advanced gastric cancer
    Nishikawa, K.
    Koizumi, W.
    Tsuburaya, A.
    Yamanaka, T.
    Morita, S.
    Fujitani, K.
    Akamaru, Y.
    Shimada, K.
    Hosaka, H.
    Nakayama, N.
    Miyashita, Y.
    Tsujinaka, T.
    Sakamoto, J.
    ANNALS OF ONCOLOGY, 2018, 29
  • [49] The Efficacy of Liposomal Irinotecan Plus Fluorouracil/Leucovorin as First-Line Therapy in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma A Single-Center Real-World Study
    Chiang, Cho-Han
    Chiang, Cho-Hung
    Chiang, Cho-Hsien
    Chiu, Jing-Huey
    Ma, Kevin Sheng-Kai
    Chen, Brian Shiian
    Luan, Yu-Ze
    Cheng, Teng-Chieh
    Hsieh, Ching-Lung
    Peng, Cheng-Ming
    PANCREAS, 2022, 51 (08) : E107 - E109
  • [50] Real-world one-year overall survival among patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with liposomal irinotecan in the NAPOLI-1 based regimen.
    Kim, George P.
    Cockrum, Paul
    Surinach, Andy
    Abushahin, Laith, I
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
12345